睿智医药 reported revenue of ¥0.56B for the period ended 2026-06-30, +5.4% year on year. Net income was ¥-0.03B, a -5.4% net margin on a 23.7% gross margin. The largest revenue line is 医药研发服务及生产外包服务收入 at 97% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.56B | +5.4% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.03B | -220.0% |
| Gross margin | 23.7% | Net margin -5.4% |
| Revenue Q/Q | +10.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药研发服务及生产外包服务收入 | ¥0.54B | 96.9% |
| 大健康及医疗业务收入 | ¥0.02B | 2.7% |
| 租金收入 | ¥0.00B | 0.4% |
| 其他收入 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.43B | 76.3% |
| R&D | ¥0.03B | 5.5% |
| SG&A | ¥0.11B | 20.4% |
| Tax & other | ¥-0.00B | -0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥1.99B |
| Total liabilities | ¥0.68B |
| Shareholders' equity | ¥1.31B |
| Equity / assets | 65.7% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | -131% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
世纪瑞尔 ・ 昌红科技 ・ *ST动力 ・ 科泰电源 ・ 瑞凌股份 ・ 安居宝 ・ 新锦动力 ・ 振东制药 ・ 新研股份 ・ 秀强股份 ・ 华中数控 ・ 雷曼光电
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies